Loading...
Phase II trial of everolimus and erlotinib in patients with platinum-resistant recurrent and/or metastatic head and neck squamous cell carcinoma
BACKGROUND: Enhanced phosphoinositide 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is one of the key adaptive changes accounting for epidermal growth factor receptor (EGFR) inhibitor-resistant growth in head and neck squamous cell carcinoma (HNSCC). We designed a phase II clinica...
Na minha lista:
| Udgivet i: | Ann Oncol |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Oxford University Press
2015
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4855241/ https://ncbi.nlm.nih.gov/pubmed/26025965 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv194 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|